title: Tamoxifen treatment reverses the adverse effects of chemotherapy-induced ovarian failure on serum lipids.
abstract: In all, 146 premenopausal women with early stage breast cancer were treated with adjuvant chemotherapy. In addition, 5-year tamoxifen treatment was started after chemotherapy to those 112 patients with hormone-receptor-positive tumours while those with hormone-receptor-negative tumours received no further therapy. The serum lipid levels were followed in both groups. The levels of serum total and low-density lipoprotein (LDL) cholesterol increased significantly after chemotherapy only in patients who developed ovarian dysfunction. Total cholesterol increased +9.5% and LDL cholesterol +16.6% in patients who developed amenorrhoea (P<0.00001 and 0.00001, respectively). The cholesterol levels did not change in patients who preserved regular menstruation after chemotherapy. After 6 months of tamoxifen therapy, the total cholesterol decreased -9.7% and the LDL cholesterol -16.7% from levels after the chemotherapy, while the cholesterol concentrations remained at increased levels in the control group (P=0.001 and P<0.0001, respectively). The high-density lipoprotein cholesterol levels did not change significantly in either tamoxifen or control group. The effects of tamoxifen treatment on serum lipids after chemotherapy have not been studied before. Our current study suggests that adjuvant tamoxifen therapy reverses the adverse effects of chemotherapy-induced ovarian failure on total and LDL cholesterol and even lowers their serum levels below the baseline.
authors.affiliation: Department of Oncology, Helsinki University Central Hospital, PO BOX 180, HUCH, FIN-00290, Helsinki, Finland.
authors.forename: L
authors.initials: L
authors.lastname: Vehmanen
authors.forename: T
authors.initials: T
authors.lastname: Saarto
authors.forename: C
authors.initials: C
authors.lastname: Blomqvist
authors.forename: M-R
authors.initials: MR
authors.lastname: Taskinen
authors.forename: I
authors.initials: I
authors.lastname: Elomaa
mesh_terms: D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology* / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D004002:Clodronic Acid / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D017697:Premenopause; D016649:Primary Ovarian Insufficiency / Q000139:chemically induced* / Q000188:drug therapy*; D011960:Receptors, Estrogen; D013629:Tamoxifen / Q000494:pharmacology* / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D008074:Lipoproteins; D011960:Receptors, Estrogen; D004002:Clodronic Acid; D013629:Tamoxifen; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate